A 69-year-old smoker with mediastinal and hilar lymphadenopathy.

Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008;122:610e6. 23. Conen D, Leuppi J, Bubendorf L, et al. Montelukast and Churg-Strauss syndrome. Swiss Med Wkly 2004;134:377e80. 24. Guilpain P, Viallard JF, Lagarde P, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002;41:535e9. 25. Solans R, Bosch JA, Selva A, et al. Montelukast and Churg-Strauss syndrome. Thorax 2002;57:183e5. 26. Stirling RG, Chung KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax 1999;54:865e6. 27. Dahlen SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006;533:40e56. 28. Iikura M, Suzukawa M, Yamaguchi M, et al. 5-Lipoxygenase products regulate basophil functions: 5-oxo-ETE elicits migration, and leukotriene B4 induces degranulation. J Allergy Clin Immunol 2005;116:578e85. 29. Rubin P, Mollison KW. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostaglandins Other Lipid Mediat 2007;83:188e97. 30. Evans JF, Ferguson AD, Mosley RT, et al. What’s all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72e8. 31. Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008;14:461e9. 32. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009;124:417e21.